A Phase 1 Multicenter, Open-Label Study of IBI3009 as Monotherapy, or in Combination with Other Anti-Cancer Therapies in Participants with Extensive-Stage Small Cell Lung Cancer

This research study is for people with advanced small cell lung cancer that cannot be treated with surgery or has spread to other parts of the body. The study is testing an investigational medication called IBI3009, which is not yet approved for general use. The main purpose of the study is to understand how safe IBI3009 is and to identify the dose that can be used in future research. Participants will receive IBI3009 as part of this early‑phase clinical trial, helping researchers learn more about potential new treatment options for small cell lung cancer.

• Adults 18+ years of age
• Diagnosed with small cell lung cancer that cannot be removed with surgery, has spread to other parts of the body, or is extensive‑stage
• Able to carry out most daily activities
• No recent major surgery
• Cannot be pregnant or breastfeeding
• No serious side effects that have not resolved from prior cancer treatments

• Receiving the investigational drug IBI3009 as an intravenous (IV) infusion either alone or in combination with other anti-cancer therapies in repeating cycles every 2–3 weeks for up to 24 months.
• Attending regular clinic visits for safety monitoring, which may include physical exams, blood tests, electrocardiograms (ECG)s, and imaging scans to evaluate tumor response.